Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, observational, open-label, 2-arm, parallel, multi-center study. Patients with HBV-associated severe acute exacerbation for whom the treatment with NRTI (such as lamivudine and entecavir) is medically recommended will be screened for eligibility. To target 74 evaluable subjects, approximately 82 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.

* Cohort 1: Lamivudine 100 mg p.o. q.d.
* Cohort 2: Entecavir 0.5 mg p.o. q.d. This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

The efficacy and safety data will be collected at baseline, 3, 5, 8, 15, 22, 29, 85, and 180 days after initiation of antiviral treatment. All assessments should be conducted based on routine practice of each hospital. Only the analysis of HBV DNA and anti-HDV will be performed in the central lab. For patients who are willing to provide the residual samples of HBV DNA assessment, the blood samples will be preserved appropriately. All AE(s) and SAE will be followed until resolution or the event is considered stable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Entecavir Plus Adefovir in Lamivudine-Resistant Patients

NCT00986778

Hepatitis B, Chronic

WITHDRAWN PHASE4

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

NCT01438424

Hepatitis B Virus HBV

COMPLETED PHASE2

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

NCT00035789

Chronic Hepatitis B

COMPLETED PHASE3

Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

NCT01848743

Chronic HBV With Severe Exacerbation

UNKNOWN PHASE3

A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

NCT00036608

Chronic Hepatitis B

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is to compare treatment response of lamivudine and entecavir in patients with spontaneous severe acute exacerbation of chronic hepatitis B.

1\. Primary objective:

• To compare the overall survival (OS) rate during observational period between lamivudine and entecavir therapy.

2\. Secondary objectives:

1. To compare the change from baseline in HBV DNA level at each visit between lamivudine and entecavir therapy.
2. To compare the proportion of subjects who have a ≥ 2 log10 decline from baseline in HBV DNA level at each visit between lamivudine and entecavir therapy.
3. To compare the change from baseline in ALT and AST level at each visit between lamivudine and entecavir therapy.
4. To compare the proportion of subjects with prolonged prothrombin time (PT) at each visit between lamivudine and entecavir therapy.
5. To compare the change from baseline in bilirubin level at each visit between lamivudine and entecavir therapy.
6. To compare the transplantation-free survival rate during observational period between lamivudine and entecavir therapy.
7. To assess the safety of lamivudine and entecavir treatments in patients with HBV-associated severe acute exacerbation.

Statistical method(s) for safety/efficacy evaluations:

1. The major analysis will be performed according to the principal of intent-to-treat population; the safety evaluation will be performed according to the safety population.
2. For primary endpoint, the time to event will be analyzed by Kaplan-Meier method and summarized as the number of observations, number of censored, median time point estimate and the 95% CI for median.
3. Secondary efficacy endpoints:

1\. Change from baseline in HBV DNA level at each visit 2. Proportion of subjects with HBV DNA response\* at each visit

* Defined as a ≥ 2 log10 decline from baseline HBV DNA level. 3. Change from baseline in ALT level at each visit 4. Change from baseline in AST level at each visit 5. Proportion of subjects with prolonged PT\* at each visit
* PT at each visit will also be assessed. 6. Change from baseline in bilirubin level at each visit 7. Transplantation-free survival rate during observational period Continuous variables will be analyzed using two-sample t-test/ Wilcoxon Rank Sum test, and categorical variables will be analyzed Chi-squared/ Fishers' exact test. Descriptive statistics including mean, standard deviation, median, minimum, maximum, 95% confidence interval will be also presented. Categorical variables will be summarized by counts and percentage in frequency table. In addition, the time to event will be analyzed by Kaplan-Meier method.

(4) The summary results of laboratory at the baseline and the end of study visit, the change from baseline to end of study visit will be summarized by descriptive statistics and paired t-test will be used under significant level 0.05.

(5) Adverse events will be coded with MedDRA and a summary frequency table of adverse events will be provided. The severity and relationship to study medication of adverse events will be summarized as well. Furthermore, if any serious adverse event had occurred, the brief summary about serious adverse event will be described and listed in tables.

(6) All statistical tests will be two-side and evaluated at the 0.05 level of significance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lamivudine 100 mg p.o. q.d.

To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.

* Cohort 1: Lamivudine 100 mg p.o. q.d.
* Cohort 2: Entecavir 0.5 mg p.o. q.d.

This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Group Type EXPERIMENTAL

Lamivudine

Intervention Type DRUG

Lamivudine 100 mg p.o. q.d.

This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Entecavir 0.5 mg p.o. q.d

To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.

* Cohort 1: Lamivudine 100 mg p.o. q.d.
* Cohort 2: Entecavir 0.5 mg p.o. q.d.

This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Group Type EXPERIMENTAL

Entecavir

Intervention Type DRUG

•Entecavir 0.5 mg p.o. q.d

This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lamivudine

Lamivudine 100 mg p.o. q.d.

This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Intervention Type DRUG

Entecavir

•Entecavir 0.5 mg p.o. q.d

This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zeffix® Baraclude®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female ≥ 20 years of age
2. HBsAg carrier with spontaneously severe acute exacerbation for whom the treatment with nucleoside and nucleotide reverse transcriptase inhibitor (NRTI) such as lamivudine and entecavir is medically recommended
3. Patients who fulfills all of the following criteria at screening:

* documented HBsAg positive for at least 6 months or anti-HBc IgM negative
* HBV DNA ≥ 2,000 IU/mL\*

\* The blood sample will be collected at screening visit, but this criterion will be checked after obtaining lab result. For patients fulfill all other criteria, they can be enrolled immediately.
* total bilirubin ≥ 2 mg/dL or prolonged prothrombin time (PT) ≥ 3 sec
* serum ALT ≥ 10 x ULN
4. Patient with sufficient renal function defined as SCr ≤ 1.5 x ULN or ClCr ≥ 50 mL/min
5. Willing and able to sign a written informed consent

Exclusion Criteria

1. Female who is pregnant/lactating
2. Patient with underlying liver cirrhosis classified as Child-Pugh class B or C
3. Patients with documented hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) co-infection
4. Patients with uncontrolled malignancy
5. History or presence of alcohol or substance abuse within 1 year prior to the initiation of NRTI treatment
6. History of hypersensitivity to any ingredient of observational drugs (Zeffix® or Baraclude®)
7. Current use of medicine which may induce hepatotoxicity
8. Use of any antiviral therapy for HBV, such as interferon-α (IFN-α) and other nucleotide/nucleoside analogues, within 6 months prior to the initiation of NRTI treatment or exposure to any treatment for more than 3 months
9. Use of any chemotherapy or immunosuppressive agents within 12 months prior to the initiation of NRTI treatment
10. Use of any investigational product, including drug and invasive medical device, within 4 weeks prior to the initiation of NRTI treatment
11. Patient with any medical or psychiatric condition, including the presence of significant abnormal laboratory values, which is considered not suitable for this study by investigator

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No